Your browser doesn't support javascript.
loading
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges, Laurence; Tannir, Nizar M; Burotto, Mauricio; McDermott, David; Plimack, Elizabeth R; Barthélémy, Philippe; Porta, Camillo; Powles, Thomas; Donskov, Frede; George, Saby; Kollmannsberger, Christian K; Gurney, Howard; Grimm, Marc-Oliver; Tomita, Yoshihiko; Castellano, Daniel; Rini, Brian I; Choueiri, Toni K; Saggi, Shruti Shally; McHenry, M Brent; Motzer, Robert J.
Afiliação
  • Albiges L; Department of Cancer Medicine, Gustave Roussy, Villejuif, France. Electronic address: laurence.albiges@gustaveroussy.fr.
  • Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Burotto M; Bradford Hill Clinical Research Center, Santiago, Chile.
  • McDermott D; Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA.
  • Plimack ER; Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
  • Barthélémy P; Medical Oncology Unit, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; ICANS, Strasbourg, France.
  • Porta C; University of Bari 'A. Moro', Bari, Italy.
  • Powles T; Department of Urology, Barts Cancer Institute, Royal Free NHS Trust, London, UK; Queen Mary University of London, London, UK.
  • Donskov F; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • George S; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Kollmannsberger CK; Department of Medicine, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
  • Gurney H; Department of Medical Oncology, Westmead Hospital, Westmead, New South Wales, Australia; Macquarie University, Sydney, New South Wales, Australia.
  • Grimm MO; Department of Urology, Jena University Hospital, Jena, Thüringen, Germany.
  • Tomita Y; Niigata University Faculty of Medicine Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Castellano D; Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Rini BI; Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Saggi SS; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey, USA.
  • McHenry MB; Department of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ESMO Open ; 5(6): e001079, 2020 11.
Article em En | MEDLINE | ID: mdl-33246931
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2020 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: ESMO Open Ano de publicação: 2020 Tipo de documento: Article País de publicação: Reino Unido